25 Jul 2024
// PRESS RELEASE
13 May 2024
// PRESS RELEASE
08 Apr 2024
// PRESS RELEASE
Latest Content by PharmaCompass
FAMAR CDMO- From early development to commercial manufacturing.
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Booth #5C27
08-10 October, 2024
Bio-Europe 2024Bio-Europe 2024
Industry Trade Show
Attending
04-06 November, 2024
Industry Trade Show
Not Confirmed
26-27 September, 2024
CONTACT DETAILS
“Ready-to-use” Solutions & Services:
Events
Webinars & Exhibitions
Severity: Warning
Message: Undefined variable $tile1
Filename: tabs/exhibitions.php
Line Number: 43
Backtrace:
File: /var/www/html/application/views/include/party/inc/tabs/exhibitions.php
Line: 43
Function: _error_handler
File: /var/www/html/application/models/CmnPec.php
Line: 1626
Function: view
File: /var/www/html/application/views/include/party/query.php
Line: 575
Function: create
File: /var/www/html/application/views/include/party/indexNew.php
Line: 86
Function: include
File: /var/www/html/application/views/commonNew.php
Line: 1368
Function: include
File: /var/www/html/application/controllers/PharmaServices.php
Line: 4587
Function: view
File: /var/www/html/index.php
Line: 224
Function: require_once
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Booth #5C27
08-10 October, 2024
Bio-Europe 2024Bio-Europe 2024
Industry Trade Show
Attending
04-06 November, 2024
Industry Trade Show
Not Confirmed
26-27 September, 2024
CORPORATE CONTENT #SupplierSpotlight
https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities
25 Jul 2024
// PRESS RELEASE
https://mideuropa.com/news/mideuropa-acquires-a-majority-stake-in-famar/
13 May 2024
// PRESS RELEASE
https://www.famar-group.com/new/new-collaboration-between-famar-and-d-sight-for-cmc-development-and-clinical-batch-manufacturing/
08 Apr 2024
// PRESS RELEASE
23 Jan 2024
// PRESS RELEASE
https://famar-group.com/new/new-collaboration-between-famar-and-lavipharm-joining-forces-in-the-production-of-pharmaceutical-products/
17 Oct 2023
// PRESS RELEASE
21 Jul 2023
// PRESS RELEASE
https://famar-group.com/new/famar-was-awarded-for-its-business-extroversion/
Details:
Under the collaboration, FAMAR will undertake the production of two pharmaceutical products recently added to Lavipharm’s portfolio of analgesic pharmaceutical products, Lonarid N (paracetamol) and Lonalgal (caffeine Anhydrous).
Lead Product(s): Paracetamol,Caffeine
Therapeutic Area: Immunology Brand Name: Lonarid N
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: LaviPharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 23, 2024
Lead Product(s) : Paracetamol,Caffeine
Therapeutic Area : Immunology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : LaviPharm
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration, FAMAR will undertake the production of two pharmaceutical products recently added to Lavipharm’s portfolio of analgesic pharmaceutical products, Lonarid N (paracetamol) and Lonalgal (caffeine Anhydrous).
Brand Name : Lonarid N
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 23, 2024
Details:
Under the agreement, Medicom has acquired the ownership of the pharmaceutical dossier of Zimed (bimatoprost), a preservative free eye drop solution, which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Brand Name: Zimed
Study Phase: ApprovedProduct Type: Small molecule
Recipient: Medicom Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 09, 2021
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Recipient : Medicom Healthcare
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under the agreement, Medicom has acquired the ownership of the pharmaceutical dossier of Zimed (bimatoprost), a preservative free eye drop solution, which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.
Brand Name : Zimed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 09, 2021
Details:
Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.
Lead Product(s): Laquinimod
Therapeutic Area: Ophthalmology Brand Name: ABR-215062
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Active Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 04, 2021
Lead Product(s) : Laquinimod
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Active Biotech
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through the agreement, Active Biotech will get the material for the clinical development of the eye-drop formulation of ABR-215062 (laquinimod), which is used for the treatment of non-infectious non-anterior uveitis.
Brand Name : ABR-215062
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 04, 2021
Services
Analytical
Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Tablet
Sub Category : Chewable / Suckable
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Tablet
Sub Category : High Potency APIs (HPAPIs)
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Tablet
Sub Category : Steroid / Hormone
Pharma Service : Drug Product Manufacturing
Pharma Service : Drug Product Manufacturing
Category : Tablet
Sub Category : Effervescent
Pharma Service : Drug Product Manufacturing
API & Drug Product Development
Packaging
Inspections and registrations
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?